DNX 2401

Drug Profile

DNX 2401

Alternative Names: Ad-delta24-RGD; Ad-DNX 2401; Ad5-Delta 24RGD; Ad5-delta24-RGD; Adenovirus DNX 2401; Adenovirus-5 delta 24 RGD; Delta 24 RGD 4C; Delta-24-RGD; Delta-24-RGDOX; DNX-2401; IE-CRAd; RGD-delta24; Tasadenoturev; VLI-01A

Latest Information Update: 09 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DNAtrix; University of Texas M. D. Anderson Cancer Center
  • Developer Clinica Universidad de Navarra; DNAtrix; Merck & Co; University of Alabama Comprehensive Cancer Center
  • Class Cancer vaccines; DNA vaccines; Oncolytic viruses
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Glioma
  • No development reported Ovarian cancer

Most Recent Events

  • 02 Jun 2017 Efficacy and safety data from the phase Ib TARGET-I trial in Glioblstoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 10 Mar 2017 Phase-II clinical trials in Glioblastoma (Combination therapy, Recurrent) in Canada (Intratumoural) (NCT02798406)
  • 03 Nov 2016 Phase-I clinical trials in Glioma (Newly diagnosed, In children, In adolescents, First-line therapy) in Spain (Intratumoural) (EudraCT2016-001577-33)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top